TRANSIT-CARE: Transitioning to Home or In-center Dialysis

Sponsor
Ciusss de L'Est de l'Île de Montréal (Other)
Overall Status
Recruiting
CT.gov ID
NCT05989659
Collaborator
Canadian Institutes of Health Research (CIHR) (Other), The Kidney Foundation of Canada (Other)
420
1
59.9
7

Study Details

Study Description

Brief Summary

For people with advanced kidney disease, deciding which type of dialysis is best can be challenging. Studies have shown that quality of life is very important to patients. It is thought that the quality of life of people receiving their dialysis at home may be better than the one of people receiving dialysis in a hospital. However, how the start of dialysis changes the quality of life of people who choose home dialysis in comparison to people choosing dialysis in a hospital is still unknown.

TRANSIT-CARE is a prospective mixed methods study following adult with advanced kidney disease who progress to dialysis and receive home or hospital-based dialysis. This study aims to examine the trajectory and change in patients' quality of life and their frailty status (health, mobility and function) before start of dialysis and up to 12-month after start. Differences between people doing home dialysis and hospital-based dialysis will be assesses taking into account people's characteristics including their gender and socio-demographics characteristics. The study will include questionnaires to measure quality of life and tools to evaluate frailty. Additionally, semi-structured interviews will be done with a diverse group of patients and caregivers before and after the initiation of dialysis to better understand their experience of transitioning to dialysis.

Condition or Disease Intervention/Treatment Phase
  • Other: Exposure: Home dialysis or facility-hemodialysis

Detailed Description

Home dialysis has been encouraged due to its clinical benefits and lower costs, leading to increased use in recent years, even among patients with a high comorbidity burden and frailty severity. Health-related quality of life (HRQoL) is reduced in patients receiving dialysis, although patients treated with home dialysis may have relatively better patient-reported outcome measures (PROMs), than those on in-center dialysis. As the home dialysis population expands to include patients with a high frailty severity, it is unknown if these benefits are preserved. More importantly, data lacks on how the transition to home or in-center dialysis is experienced by patients and caregivers and whether changes in HRQoL and frailty impact this experience.

Objectives

  1. Determine and compare the trajectory of HRQoL, frailty and caregiver burden during the chronic kidney disease (CKD)-to-dialysis transition. (QUANTI)

  2. Examine the experience of participants during their progression from CKD to dialysis. (QUALI)

  3. Understand how HRQoL, frailty, and dialysis modality influence patients' and caregivers' experience of transition. (QUANTI+QUALI)

Design and Research Plan TRANSIT-CARE is a 5-year multicenter mixed-methods study of patients with advanced CKD and their caregivers across 12 Canadian centers, with active patient-partner engagement.

QUANTITATIVE Participant will be followed every 3-months (from estimated glomerular filtration rate [eGFR] <12 mL/min/1.73m2) and up to 12-month after dialysis start (4-week, 3-, 6-,12-month).

Target recruitment: 420 patients / 165 caregivers. Dialysis modality will be defined as the chosen modality at baseline visit, and dichotomized as home dialysis (peritoneal or home hemodialysis) and in-center dialysis.

Changes in PROMs and frailty will be assessed using multivariable mixed linear spline regression analysis with each measure used as a continuous variable adjusted for baseline scores, chosen dialysis modality (exposure), dialysis start (time-dependent variable) and prespecified potential confounders.

QUALITATIVE Semi-structured interviews will be conducted with 30 patients and 30 caregivers (from three centers) before and after dialysis initiation.

Thematic analysis will be used to identify patient and caregiver perceptions of home and in-center dialysis, their reactions to dialysis initiation (e.g., feelings of empowerment or loss, life disruption) and perceived burden for caregivers.

Data integration Data from the qualitative and quantitative components will be integrated at time of analysis using tables and joint displays.

Study Design

Study Type:
Observational
Anticipated Enrollment :
420 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Transitioning Patients With Advanced Chronic Kidney Disease to Home or In-center Dialysis: Understanding the Experience and Quality of Life for Patients and Their Caregivers
Actual Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Dec 30, 2026
Anticipated Study Completion Date :
Dec 30, 2027

Arms and Interventions

Arm Intervention/Treatment
Patient - Home Dialysis

Patients transitioning to home dialysis

Other: Exposure: Home dialysis or facility-hemodialysis
Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis

Patient - Facility Hemodialysis

Patients transitioning to facility hemodialysis

Other: Exposure: Home dialysis or facility-hemodialysis
Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis

Caregivers - Home dialysis

Caregivers of patients transitioning to home dialysis

Other: Exposure: Home dialysis or facility-hemodialysis
Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis

Caregivers - Facility Hemodialysis

Caregivers of patients transitioning to facility hemodialysis

Other: Exposure: Home dialysis or facility-hemodialysis
Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis

Outcome Measures

Primary Outcome Measures

  1. Change in Kidney Disease Quality of Life - 36 (KDQOL-36) - Patients [From study inclusion until 12-months after dialysis start.]

    Scale from 0-100 (0=poor , 100 = excellent )

  2. Change in 'Zarit' burden Interview (ZBI) - Caregivers [From study inclusion until 12-months after dialysis start.]

    Scale 0-88 (0=no/little burden, 88 = severe burden)

Secondary Outcome Measures

  1. Change in Fried Frailty phenotype [From study inclusion until 12-months after dialysis start.]

    5 components (slowness, weakness, weight loss, low physical activity, exhaustion) with classification as no-frail, pre-frail or frail

  2. Change in Clinical Frailty Scale [From study inclusion until 12-months after dialysis start.]

    Scale 1 (very fit) to 9 (terminally ill)

  3. Change in Hospital Anxiety and Depression - Patients [From study inclusion until 12-months after dialysis start.]

    14-item scale (7 anxiety, 7 depression) with score ≥8 used as cut-off for increased risk of depression and anxiety

  4. Change in Short-form (SF)-36 - Caregivers [From study inclusion until 12-months after dialysis start.]

    Scale from 0-100 (0=poor , 100 = excellent )

Other Outcome Measures

  1. Semi-structured interviews with patients and caregivers [First interview between study start and dialysis initiation / Second interview between dialysis start and up to 12-month after dialysis start.]

    2 interviews with patients and caregivers

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Adults followed in advanced CKD clinic,

  2. estimated glomerular filtration rate (eGFR) <12 mL/min/1.73m2 103,

  3. Have chosen their dialysis modality,

  4. Understand English or French.

Exclusion Criteria:
  1. Orientation toward conservative treatment,

  2. Planned kidney transplantation < 6 months,

  3. Unable to provide consent due to severe cognitive or psychiatric disease,

  4. Previous treatment with dialysis > 3 months,

  5. Life expectancy < 6 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital Maisonneuve-Rosemont Montréal Quebec Canada H1T 2M4

Sponsors and Collaborators

  • Ciusss de L'Est de l'Île de Montréal
  • Canadian Institutes of Health Research (CIHR)
  • The Kidney Foundation of Canada

Investigators

  • Principal Investigator: Annie-Claire Nadeau-Fredette, MD, CIUSSS de l'Est-de-l'Ile-de-Montréal

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ciusss de L'Est de l'Île de Montréal
ClinicalTrials.gov Identifier:
NCT05989659
Other Study ID Numbers:
  • 2022_2973
First Posted:
Aug 14, 2023
Last Update Posted:
Aug 14, 2023
Last Verified:
Jul 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ciusss de L'Est de l'Île de Montréal
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 14, 2023